Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
733.04 ^USD	-1.20%		-7.97%	-5.03%

16/01	Where the Money's Moving
16/01	Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion	MT

Transcript : Regeneron Pharmaceuticals, Inc. - Special Call

Published on 12/10/2025 at 08:50 pm IST - Modified on 12/10/2025 at 11:05 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the Regeneron conference call to discuss its Lynozyfic development program. My name is Shannon, and I will be your operator for today's

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Regeneron Pharmaceuticals, Inc.

16/01	Where the Money's Moving
16/01	Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion	MT
16/01	Some drugmakers quietly concerned about legal risk with speedy FDA review program	RE
14/01	Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs	MT
13/01	Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating	MT
13/01	Raymond James Adjusts PT on Regeneron Pharmaceuticals to $820 From $800, Keeps Outperform Rating	MT
13/01	Regeneron Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02:15 PM
09/01	Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $911 From $818, Maintains Outperform Rating	MT
09/01	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,200,000, According to a Recent SEC Filing	MT
08/01	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $914 From $807, Maintains Buy Rating	MT
08/01	Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology	CI
08/01	RBC Raises Price Target on Regeneron Pharmaceuticals to $766 From $708, Keeps Sector Perform Rating	MT
07/01	BofA Securities Upgrades Regeneron Pharmaceuticals to Buy From Underperform, Raises Price Target to $860 From $627	MT
07/01	Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says	MT
01/01	US FDA declines to approve Outlook's eye disease drug for second time in 2025	RE
29/12	Founder-CEOs: a driver of stock outperformance
26/12	Johnson & Johnson halts mid-stage trial of experimental eczema drug	RE
24/12	Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update	DJ
23/12	Sanofi, Regeneron Say Bronchial Asthma Treatment Approved in Japan for Children	MT
23/12	Sanofi, Regeneron's Dupixent Wins Expanded Japanese Approval for Bronchial Asthma	MT
23/12	Sanofi and Regeneron's Dupixent approved in Japan for children with bronchial asthma	RE
23/12	Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma	CI
23/12	Vyriad, Inc. announced that it has received $85 million in funding from Regeneron Pharmaceuticals, Inc., Mayo Clinic Ventures, Mirae Asset Venture Investment Co., Ltd., Southeast Minnesota Capital Fund LLC, Stine Seed Farm, Inc. and other investors	CI
19/12	Nothing to See, Cut Rates
19/12	Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating	MT